CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The NanoLymphoma project develops a novel therapeutic platform using nanofilaments to target multiple proteins on lymphoma cells. This approach aims to improve treatment outcomes for patients with aggressive B-cell lymphoma by inducing effective tumor cell death.
Immunotherapy using antibodies targeting the cell surface has led to important clinical advances in patients with cancer, exemplified by CD20-antibodies that are first-line treatment in patients with B-cell lymphoma.
However, diffuse large B-cell lymphoma (DLBCL), the most common and aggressive form of B-cell lymphoma worldwide, is still incurable in 40% of patients.
These patients have poor prognosis due to treatment failure or relapse upon therapy with CD20-antibodies (260,000 mortalities worl…
STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
